AIM
ARK Investment Management’s Recursion Pharmaceuticals RXRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $167M | Sell |
32,988,631
-1,826,871
| -5% | -$9.24M | 1.22% | 21 |
|
|
2025
Q1 | $184M | Buy |
34,815,502
+2,469,104
| +8% | +$13.1M | 1.84% | 17 |
|
|
2024
Q4 | $219M | Sell |
32,346,398
-422,788
| -1% | -$2.86M | 1.82% | 16 |
|
|
2024
Q3 | $216M | Buy |
32,769,186
+4,626,268
| +16% | +$30.5M | 1.98% | 16 |
|
|
2024
Q2 | $211M | Buy |
28,142,918
+3,555,357
| +14% | +$26.7M | 1.87% | 17 |
|
|
2024
Q1 | $245M | Buy |
24,587,561
+3,933,274
| +19% | +$39.2M | 1.7% | 16 |
|
|
2023
Q4 | $204M | Buy |
20,654,287
+13,777,689
| +200% | +$136M | 1.21% | 24 |
|
|
2023
Q3 | $52.6M | Buy |
6,876,598
+2,138,081
| +45% | +$16.4M | 0.4% | 39 |
|
|
2023
Q2 | $35.4M | Buy |
4,738,517
+1,161,655
| +32% | +$8.68M | 0.23% | 53 |
|
|
2023
Q1 | $23.9M | Buy |
3,576,862
+477,372
| +15% | +$3.18M | 0.16% | 64 |
|
|
2022
Q4 | $23.9M | Sell |
3,099,490
-260,321
| -8% | -$2.01M | 0.21% | 62 |
|
|
2022
Q3 | $35.7M | Buy |
3,359,811
+627,724
| +23% | +$6.68M | 0.25% | 55 |
|
|
2022
Q2 | $16.7M | Sell |
2,732,087
-95,076
| -3% | -$582K | 0.1% | 103 |
|
|
2022
Q1 | $20.2M | Buy |
2,827,163
+595,150
| +27% | +$4.26M | 0.08% | 109 |
|
|
2021
Q4 | $38.2M | Sell |
2,232,013
-361,823
| -14% | -$6.2M | 0.12% | 103 |
|
|
2021
Q3 | $59.7M | Buy |
2,593,836
+215,161
| +9% | +$4.95M | 0.14% | 102 |
|
|
2021
Q2 | $86.8M | Buy |
+2,378,675
| New | +$86.8M | 0.16% | 96 |
|